Eliana Merle
Stock Analyst at UBS
(3.52)
# 932
Out of 5,055 analysts
96
Total ratings
47.89%
Success rate
6.67%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eliana Merle
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRNA Moderna | Maintains: Buy | $70 → $40 | $24.77 | +61.49% | 8 | Oct 23, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $72 → $82 | $66.39 | +23.51% | 4 | Sep 12, 2025 | |
| GOSS Gossamer Bio | Upgrades: Buy | $1.25 → $9 | $2.71 | +232.10% | 3 | Sep 10, 2025 | |
| ALT Altimmune | Maintains: Buy | $26 → $24 | $4.17 | +475.54% | 2 | Aug 13, 2025 | |
| RAPT RAPT Therapeutics | Maintains: Neutral | $8 → $9 | $28.85 | -68.80% | 4 | Aug 12, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $458 → $523 | $529.21 | -1.17% | 5 | Aug 12, 2025 | |
| ANAB AnaptysBio | Maintains: Neutral | $18 → $20 | $33.82 | -40.86% | 5 | Aug 12, 2025 | |
| ASND Ascendis Pharma | Maintains: Buy | $306 → $307 | $204.40 | +50.20% | 2 | Aug 8, 2025 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $113 → $114 | $54.73 | +108.30% | 3 | Aug 5, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $403 → $550 | $449.16 | +22.45% | 3 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $45 → $12 | $18.81 | -36.20% | 1 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $8 | $2.41 | +231.95% | 1 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $5.5 | $5.28 | +4.17% | 3 | Jun 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $74 → $21 | $10.57 | +98.68% | 6 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $70 | $64.94 | +7.79% | 3 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $44 | $20.33 | +116.43% | 8 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $109 | $54.25 | +100.92% | 4 | Jan 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5 → $2.2 | $1.34 | +64.79% | 4 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $71 | $67.75 | +4.80% | 2 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $15.73 | +78.00% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $7.75 | +54.84% | 1 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $3 | $3.99 | -24.81% | 1 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $97 → $131 | $103.09 | +27.07% | 6 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3 → $5 | $19.51 | -74.37% | 3 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $18 | $22.56 | -20.21% | 2 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $45 → $42 | $29.88 | +40.56% | 4 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $14.37 | +53.10% | 1 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $47 | $11.51 | +308.34% | 1 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $9.49 | +68.69% | 2 | May 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $192 → $134 | $31.31 | +327.98% | 3 | Aug 19, 2020 |
Moderna
Oct 23, 2025
Maintains: Buy
Price Target: $70 → $40
Current: $24.77
Upside: +61.49%
BridgeBio Pharma
Sep 12, 2025
Maintains: Buy
Price Target: $72 → $82
Current: $66.39
Upside: +23.51%
Gossamer Bio
Sep 10, 2025
Upgrades: Buy
Price Target: $1.25 → $9
Current: $2.71
Upside: +232.10%
Altimmune
Aug 13, 2025
Maintains: Buy
Price Target: $26 → $24
Current: $4.17
Upside: +475.54%
RAPT Therapeutics
Aug 12, 2025
Maintains: Neutral
Price Target: $8 → $9
Current: $28.85
Upside: -68.80%
Madrigal Pharmaceuticals
Aug 12, 2025
Maintains: Buy
Price Target: $458 → $523
Current: $529.21
Upside: -1.17%
AnaptysBio
Aug 12, 2025
Maintains: Neutral
Price Target: $18 → $20
Current: $33.82
Upside: -40.86%
Ascendis Pharma
Aug 8, 2025
Maintains: Buy
Price Target: $306 → $307
Current: $204.40
Upside: +50.20%
BioMarin Pharmaceutical
Aug 5, 2025
Maintains: Buy
Price Target: $113 → $114
Current: $54.73
Upside: +108.30%
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Buy
Price Target: $403 → $550
Current: $449.16
Upside: +22.45%
Jul 21, 2025
Downgrades: Neutral
Price Target: $45 → $12
Current: $18.81
Upside: -36.20%
Jul 15, 2025
Maintains: Buy
Price Target: $4 → $8
Current: $2.41
Upside: +231.95%
Jun 26, 2025
Downgrades: Neutral
Price Target: $12 → $5.5
Current: $5.28
Upside: +4.17%
May 15, 2025
Maintains: Buy
Price Target: $74 → $21
Current: $10.57
Upside: +98.68%
May 13, 2025
Maintains: Buy
Price Target: $72 → $70
Current: $64.94
Upside: +7.79%
Apr 29, 2025
Initiates: Overweight
Price Target: $44
Current: $20.33
Upside: +116.43%
Jan 31, 2025
Maintains: Buy
Price Target: $42 → $109
Current: $54.25
Upside: +100.92%
Jan 28, 2025
Maintains: Neutral
Price Target: $5 → $2.2
Current: $1.34
Upside: +64.79%
Jan 8, 2025
Maintains: Buy
Price Target: $65 → $71
Current: $67.75
Upside: +4.80%
Jan 7, 2025
Initiates: Buy
Price Target: $28
Current: $15.73
Upside: +78.00%
Nov 12, 2024
Initiates: Buy
Price Target: $12
Current: $7.75
Upside: +54.84%
Nov 12, 2024
Initiates: Neutral
Price Target: $3
Current: $3.99
Upside: -24.81%
Sep 18, 2024
Maintains: Neutral
Price Target: $97 → $131
Current: $103.09
Upside: +27.07%
Apr 4, 2024
Maintains: Neutral
Price Target: $3 → $5
Current: $19.51
Upside: -74.37%
Mar 27, 2024
Maintains: Buy
Price Target: $19 → $18
Current: $22.56
Upside: -20.21%
May 19, 2023
Maintains: Buy
Price Target: $45 → $42
Current: $29.88
Upside: +40.56%
Oct 13, 2022
Initiates: Buy
Price Target: $22
Current: $14.37
Upside: +53.10%
Jun 23, 2022
Maintains: Buy
Price Target: $51 → $47
Current: $11.51
Upside: +308.34%
May 21, 2021
Initiates: Buy
Price Target: $16
Current: $9.49
Upside: +68.69%
Aug 19, 2020
Maintains: Neutral
Price Target: $192 → $134
Current: $31.31
Upside: +327.98%